SHARE

Anavex Life Sciences Corp (OTCMKTS:AVXL) a known clinical-stage biopharmaceutical firm working on drug candidates to treat CNS diseases and Alzheimer presented promising preclinical data for its ANAVEX 3-71 and ANAVEX 2-73 drug candidates. The data was disclosed in two separate presentations at the world-famous 2015 International Conference on ‘Alzheimer’s and Parkinson’s Diseases’ in France.

The details

Tangui Maurice, PhD who is a part of the Scientific Advisory Board of Anavex Life established for the first time the crucial role of S1R via ‘S1R Knock out’ on memory and survival in the existence of amyloid. At present, drug candidate ANAVEX 2-73 is in Phase 2a study in patients suffering from Alzheimer. The Phase 1 trial is concluded with a clean data profile. In last preclinical trials, drug candidate ANAVEX 2-73 showed potential to reverse or halt Alzheimer’s disease. Also, positive preclinical findings highlight the potential for ANAVEX 2-73 as a main drug to cure other CNS disorders.

The presentation

Anavex’s second presentation was on ANAVEX 3-71 which was earlier called as AF710B. It is a promising and novel preclinical drug with a pioneering mechanism of action said to enhance cognition and neuroprotection in fatal disease Alzheimer. It can be better called as CNS-penetrable mono treatment that bridges treatment of cognitive impairments and disease modifications. There are numerous benefits including lessening of inflammation and mitochondrial dysfunctions.

Promising data

Christopher U. Missling, PhD, the CEO of Anavex stated that with the presented data the company is optimistic to have the two drugs currently in the trial process and will update on the progress of the study in next quarter. The company’s lead drug candidate ANAVEX 3-71 demonstrated encouraging broad therapeutic advantages in Alzheimer’s disease provided its capacity to boost neuroprotection and cognition via SIR activation.

On Wednesday’s trading session, Anavex stock price jumped 9% to close at $0.230 at volume of 1.76 million.

SHARE
Previous articleMedical Marijuana Inc (OTCMKTS:MJNA) Updates On Kannaway Sales Growth
Next articleCannabis Science Inc (OTCMKTS:CBIS) Finalizes A One-Year Deal With Derwin A. Wallace
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.

LEAVE A REPLY